John P. Longenecker, PhD recently served as president and Chief Executive Officer of HemaQuest Pharmaceuticals, a private biotechnology company developing treatment for hemoglobinopathies, including sickle cell disease and beta thalassemia, until May of 2014. Dr. Longenecker has 30 years’ experience in the biotech/pharmaceutical industry, including the startup and growth of multiple biotechnology companies. He has led efforts in all aspects of company development from startup venture capital funding, initial and secondary public offerings, corporate partnering, management of collaborations and mergers and acquisitions. Prior to HemaQuest, Dr. Longenecker was president, Chief Executive Officer and Director of Favrille, Inc., a public biotechnology company developing personalized cancer vaccines for lymphoma. In 1992, he joined DepoTech (the precursor to Pacira) as Senior Vice President of Research, Development and Operations, and then served as President and Chief Operating Officer from February 1998 to March 1999. Under his leadership, DepoTech took its lead product, DepoCyt, from early pre-clinical research and development through to commercial launch. Following SkyePharma PLC’s acquisition of DepoTech in 1999, Dr. Longenecker served as President for the U.S. Operations of SkyePharma Inc. and as a Member of the Executive Committee for SkyePharma PLC. From 1982 to 1992, he was at Scios (Cal Bio), a biotechnology company in the San Francisco Bay Area, where he served as Vice President and Director of Development. He was also a Director of a number of Cal Bio subsidiaries during this period, including Meta Bio and Karo Bio. Dr. Longenecker obtained a BS from Purdue University in Lafayette, Indiana and a PhD in Biochemistry from The Australian National University in Canberra, Australia. He was a post-doctoral fellow at Stanford University from 1980 to 1982. John P. Longenecker, PhD recently served as president and Chief Executive Officer of HemaQuest Pharmaceuticals, a private biotechnology company developing treatment for hemoglobinopathies, including sickle cell disease and beta thalassemia, until May of 2014. Dr. Longenecker has 30 years’ experience in the biotech/pharmaceutical industry, including the startup and growth of multiple biotechnology companies. He has led efforts in all aspects of company development from startup venture capital funding, initial and secondary public offerings, corporate partnering, management of collaborations and mergers and acquisitions. Prior to HemaQuest, Dr. Longenecker was president, Chief Executive Officer and Director of Favrille, Inc., a public biotechnology company developing personalized cancer vaccines for lymphoma. In 1992, he joined DepoTech (the precursor to Pacira) as Senior Vice President of Research, Development and Operations, and then served as President and Chief Operating Officer from February 1998 to March 1999. Under his leadership, DepoTech took its lead product, DepoCyt, from early pre-clinical research and development through to commercial launch. Following SkyePharma PLC’s acquisition of DepoTech in 1999, Dr. Longenecker served as President for the U.S. Operations of SkyePharma Inc. and as a Member of the Executive Committee for SkyePharma PLC. From 1982 to 1992, he was at Scios (Cal Bio), a biotechnology company in the San Francisco Bay Area, where he served as Vice President and Director of Development. He was also a Director of a number of Cal Bio subsidiaries during this period, including Meta Bio and Karo Bio. Dr. Longenecker obtained a BS from Purdue University in Lafayette, Indiana and a PhD in Biochemistry from The Australian National University in Canberra, Australia. He was a post-doctoral fellow at Stanford University from 1980 to 1982.

Oncology